Amgen Officer and VP - Mike Narachi - Joins SinusPharmas Board of Directors

Amgen Officer and Vice President Mike Narachi has joined the Board of Directors of SinusPharma, the company dedicated to innovative sinus care therapies. Mr. Narachis experience with clinical development strategies and commercial product development will contribute significantly as SinusPharma builds its new subsidiary, SinusPharmaceuticals Research.

October 7, 2002, CARPINTERIA, CA -- Amgen Officer and Vice President Mike Narachi has joined the Board of Directors of SinusPharma, the company dedicated to innovative sinus care therapies. Mr. Narachis experience with clinical development strategies and commercial product development will contribute significantly as SinusPharma builds its new subsidiary, SinusPharmaceuticals Research.

Mikes strong background in research and development, extensive, hands-on experience with the FDAs regulatory process, and considerable business acumen strengthens SinusPharmas Board. His immediate involvement in our product strategy development and clinical/regulatory approach to the FDA is accelerating the implementation of our plans," said John Wilczak, Chairman and CEO of SinusPharma.

I'm very pleased to join the board of SinusPharma. They have a great team with exciting, valuable products in development that are highly likely to meet their regulatory and commercial success hurdles. These products, coupled with an innovative pharmacy services model, poise the company to have a dramatic impact on patients with chronic sinusitis," stated Mike Narachi, Amgen Officer and Vice President.

Mr. Narachi is General Manager of Amgens Anemia Business. In this role, Mr. Narachi leads an integrated medical, marketing, and sales team whose chief aim is to eliminate anemia and its complications." Today, approximately one million U.S. patients receive treatment for their anemia with Amgens EPO (trade names EPOGEN® and PROCRIT®). Global sales of epoetin alpha are approximately $6 billion, forecasted to exceed $10 billion by 2005.

Mr. Narachi joined Amgen in July 1984 as a Molecular Biology Research Associate. Since that time, he has held various positions throughout the organization including: Product Development Team Leader for NEUPOGEN®; Director of Clinical Operations in Thousand Oaks, CA and Cambridge, UK; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operating Officer of Amgen BioPharma, Amgens Colorado-based company which developed new therapies for Inflammatory Diseases; and Vice President, Licensing & Business Development.

About SinusPharma:
SinusPharma, Inc. is a holding company specializing in proprietary treatments for sinus disorders. SinusPharma currently has two wholly-owned subsidiaries, SinusPharmacy Corporation and SinusPharmaceuticals Research Corporation, and a related portfolio of intellectual property. SinusPharmacy is a specialty pharmacy focused on providing custom-formulated prescription drugs and doctor/patient management services that support the treatment of chronic sinus disorders. In September 2000, SinusPharmacy launched its breakthrough SinuNEBTM treatment system that utilizes nebulized medication therapy to topically treat sinus disorders. SinusPharmaceuticals Research Corporation is a pharmaceutical development company that will take promising proprietary medication formulations through the FDA investigational new drug application process. On the net: SinusPharmas website: www.sinuspharma.com

###
For additional information, please contact Kirsten Ayars, Director of Corporate Communications at 805-684-2539 x 245.